Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma
- 18 March 2004
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 205 (2) , 207-214
- https://doi.org/10.1016/j.canlet.2003.10.010
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Cytotoxicity in glioma cells due to interleukin-12 and interleukin-18—stimulated macrophages mediated by interferon-γ regulated by nitric oxideJournal of Neurosurgery, 2003
- Macrophages in tumor-draining lymph node with different characteristics induce T-cell apoptosis in patients with advanced stage-gastric cancerInternational Journal of Cancer, 2003
- Immune Responses and Prediction of Major Infection in Patients Undergoing Transhiatal or Transthoracic Esophagectomy for CancerAnnals of Surgery, 2003
- Natural killer, but not natural killer T, cells play a necessary role in the promotion of an innate antitumor response induced by IL‐18International Journal of Cancer, 2002
- Enhanced IL-18 expression in common skin tumorsImmunology Letters, 2001
- In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in miceGene Therapy, 2001
- Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cellsCancer Gene Therapy, 2000
- Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cellsCancer Gene Therapy, 2000
- Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administrationCancer Gene Therapy, 2000
- Antitumor Effects on Mouse Melanoma Elicited by Local Secretion of Interleukin-12 and Their Enhancement by Treatment with Interleukin-18Cancer Investigation, 2000